Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
- Authors: Knyazev O.V.1,2,3, Zvyaglova M.Y.1, Kagramanova A.V.1, Li I.A.1, Sabelnikova E.A.1, Lishchinskaya A.A.1, Kulakov D.S.1,3, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Ryzhyh State Scientific Centre of Coloproctology
- Research Institute of Health Organization and Medical Management
- Issue: Vol 93, No 2 (2021)
- Pages: 150-157
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/64705
- DOI: https://doi.org/10.26442/00403660.2021.02.200624
- ID: 64705
Cite item
Full Text
Abstract
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohn’s disease (CD), treated with original medicine infliximab (IFX) “Remicaide” and its biosimilars.
Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%) и 76 CD patients (49.4%), treated with original medicine IFX Remicade and its biosimilars. In our study we did not include patients, who previously underwent induction treatment with IFX and its biosimilar.
Results. Among 78 UC patients, IFX was cancelled in 25 (32.0%) patients and they were switched to the other anti-TNF inhibitor or medicine with the another mechanism of action; in patients group, treated with biosimilar – 16 (20.5%) and 9 (11.5%) patients, who were interchanged biosimilar and/or original IFX. Among 76 CD patients IFX was cancelled in 20 (26.3%) patients: 11 (14.5%) patients in group, treated with similar trade name biosimilar, 8 (10.5%) patients, who were interchanged biosimilar and/or original IFX and 1 patient (1,3%), receiving original IFX. We found no difference in the secondary loss of response and adverse events in patients with CD and UC, switched from original IFX to biosimilar (p=0.6257 and p=0.6635, correspondingly). The frequency of the secondary loss of response or adverse events in patients with UC and CD, switched from original IFX to IFX biosimilar, was similar (p>0.05).
Conclusion. Approximately 30% of IBD patients, receiving IFX biosimilar, will be switched to the other anti-TNF therapy or medicine with the another mechanism of action because of secondary loss of response or adverse events.
Full Text
##article.viewOnOriginalSite##About the authors
O. V. Knyazev
Loginov Moscow Clinical Scientific Center; Ryzhyh State Scientific Centre of Coloproctology; Research Institute of Health Organization and Medical Management
Email: asfold@mail.ru
ORCID iD: 0000-0001-7250-0977
д.м.н., зав. отд-нием воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова», проф. научно-образовательного отд. ФГБУ «НМИЦ колопроктологии им. А.Н. Рыжих», вед. специалист организационно-методического отд. по колопроктологии ГБУ «НИИ организации здравоохранения и медицинского менеджмента»
Russian Federation, Moscow; Moscow; MoscowM. Yu. Zvyaglova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-7937-2346
мл. науч. сотр. отд-ния воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова»
Russian Federation, MoscowA. V. Kagramanova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-3818-6205
к.м.н., ст. науч. сотр. отд-ния воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова»
Russian Federation, MoscowI. A. Li
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-9508-7502
д.м.н., врач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова»
Russian Federation, MoscowE. A. Sabelnikova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0001-7519-2041
д.м.н., ст. науч. сотр. отд-ния невоспалительной патологии кишечника, зам. дир. по научной работе
Russian Federation, MoscowA. A. Lishchinskaya
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0001-7891-2702
к.м.н., ст. науч. сотр. отд-ния воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова»
Russian Federation, MoscowD. S. Kulakov
Loginov Moscow Clinical Scientific Center; Research Institute of Health Organization and Medical Management
Email: asfold@mail.ru
ORCID iD: 0000-0002-0855-5217
мл. науч. сотр. отд-ния воспалительных заболеваний кишечника ГБУЗ «МКНЦ им. А.С. Логинова», специалист организационно-методического отд. по колопроктологии ГБУ «НИИ организации здравоохранения и медицинского менеджмента»
Russian Federation, Moscow; MoscowA. I. Parfenov
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: asfold@mail.ru
ORCID iD: 0000-0002-9782-4860
д.м.н., проф., зав. отд. патологии кишечника ГБУЗ «МКНЦ им. А.С. Логинова»
Russian Federation, MoscowReferences
- Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4:247-61. doi: 10.1007/s40744-017-0073-3
- Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18:583-92. doi: 10.1016/j.autrev.2018.12.009
- Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685-96. doi: 10.1016/j.cgh.2016.05.023
- Kent D, Rickwood S, Di Biase S. Disruption and maturity: the next phase of biologics. 2017. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf?_=1518214264988
- Van den Hoven A. Biosimilar medicines clinical use: an experience-based EU perspective. 2017. Available at: https://www.medicinesforeurope.com/docs/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf
- IQVIA. The impact of biosimilar competition in Europe. 2018. Available at: https://ec.europa.eu/docsroom/documents/31642
- QuintilesIMS. The impact of biosimilar competition in Europe. 2017. Available at: http://ec.europa.eu/growth/content/impact-biosimilar-competition-price-volume-and-market-share-update-2017-0_en
- EMA Guideline. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2015. Available at: http://www.ema.europa.eu/docs/en_GB/documentJibrary/Scientific_guideline/2015/01 /WC500180219.pdf
- Князев О.В., Шкурко Т.В., Каграманова А.В. и др. Оценка эффективности и сравнительная частота нежелательных явлений у пациентов с язвенным колитом, получающих оригинальный препарат инфликсимаб и его биосимиляр. Наблюдение в течение года. Терапевтический архив. 2019;91(8):42-6 [Knyazev OV, Shkurko TV, Kagramanova AV, et al. Evaluation of the effectiveness and comparative frequency of adverse events in patients with ulcerative colitis receiving the original drug infliximab and its biosimilar. Observation for a year. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):42-6 (In Russ.)]. doi: 10.26442/00403660.2019.08.000331
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;59(1):6-30 [Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical recommendations of the Russian gastroenterological Association and the Association of coloproctologists of Russia on the diagnosis and treatment of ulcerative colitis. Coloproctology. 2017;59(1):6-30 (In Russ.)].
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;60(2):7-29 [Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical recommendations of the Russian gastroenterological Association and the Association of coloproctologists of Russia for the diagnosis and treatment of Crohn’s disease. Coloproctology. 2017;60(2):7-29 (In Russ.)].
- Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514. doi: 10.1016/s0140-6736(80)92767-1
- Brown SR, Haboubi N, Hampton J, et al. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10:8-29. doi: 10.1111/j.1463-1318.2008.01682.x
- Mokhele NN, Tomson SR, Watermeyer GA. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S Afr J Surg. 2017;55(3):20-6
- Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn’s Colitis. 2015;9(Issue 1):4-25. doi: 10.1016/j.crohns.2014.08.012
- Biosimilars in the EU. What I need to know about biosimilar medicines. Available at: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
- Biosimilars action plan: balancing innovation and competition. 2018. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm613761.pdf
- Emond B, Sadik K, Lafeuille M-H, et al. Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infiximab Biosimilar or Remaining on Originator Infiximab
- (REMICADE) [abstract]. Arthritis Rheumatol. 2019;71(Suppl. 10). doi: 10.1097/MEG.0000000000001113
- Luber R, O’Neill R, Singh S, Irving P. Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch. J Crohns Colitis. 2020;14(Suppl. 1):S426-S427. doi: 10.1093/ecco-jcc/jjz203.614)